https://www.selleckchem.com/pr....oducts/kg-501-2-naph
Cancer-associated macrophage-like cells (CAMLs) are a potential peripheral blood biomarker for disease progression. This study used data from a phase 2 clinical trial to evaluate prognostic utility of CAMLs for locally advanced non-small-cell lung cancer treated with definitive chemoradiotherapy (CRT) and atezolizumab (DETERRED; ClinicalTrials.gov NCT02525757). Sample collection occurred at baseline (T, during CRT (T1), at end of CRT (T2), and at first follow-up (T3). CAMLs were captured and quantified by the
Like
Comment
Share
